Quantinno Capital Management LP Acquires 31,746 Shares of Haleon plc (NYSE:HLN)

Quantinno Capital Management LP grew its holdings in shares of Haleon plc (NYSE:HLN) by 6.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 489,961 shares of the company’s stock after purchasing an additional 31,746 shares during the period. Quantinno Capital Management LP’s holdings in Haleon were worth $5,184,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HLN. Chartwell Investment Partners LLC raised its stake in Haleon by 107.8% during the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock valued at $5,030,000 after buying an additional 246,594 shares during the last quarter. Townsquare Capital LLC raised its position in shares of Haleon by 29.8% in the 3rd quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock worth $5,032,000 after purchasing an additional 109,217 shares during the last quarter. Cetera Investment Advisers boosted its stake in Haleon by 106.3% in the 1st quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares in the last quarter. Cetera Advisors LLC grew its position in Haleon by 524.3% during the 1st quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock valued at $696,000 after purchasing an additional 68,857 shares during the last quarter. Finally, FORA Capital LLC bought a new stake in Haleon during the 3rd quarter valued at about $1,026,000. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HLN shares. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley upped their price objective on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Price Performance

HLN opened at $9.67 on Friday. The company’s 50-day simple moving average is $9.83 and its two-hundred day simple moving average is $9.47. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80. The stock has a market capitalization of $43.77 billion, a P/E ratio of 28.44, a P/E/G ratio of 2.93 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.